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Abstract
Background: Many children with chronic disease use complementary therapies. Anthroposophic treatment for
paediatric chronic disease is provided by physicians and differs from conventional treatment in the use of special
therapies (art therapy, eurythmy movement exercises, rhythmical massage therapy) and special medications. We
studied clinical outcomes in children with chronic diseases under anthroposophic treatment in routine outpatient
settings.
Methods:  In conjunction with a health benefit program, consecutive outpatients starting anthroposophic
treatment for any chronic disease participated in a prospective cohort study. Main outcome was disease severity
(Disease and Symptom Scores, physicians' and caregivers' assessment on numerical rating scales 0–10). Disease
Score was documented after 0, 6, and 12 months, Symptom Score after 0, 3, 6, 12, 18, and 24 months.
Results: A total of 435 patients were included. Mean age was 8.2 years (standard deviation 3.3, range 1.0–16.9
years). Most common indications were mental disorders (46.2% of patients; primarily hyperkinetic, emotional, and
developmental disorders), respiratory disorders (14.0%), and neurological disorders (5.7%). Median disease
duration at baseline was 3.0 years (interquartile range 1.0–5.0 years). The anthroposophic treatment modalities
used were medications (69.2% of patients), eurythmy therapy (54.7%), art therapy (11.3%), and rhythmical
massage therapy (6.7%). Median number of eurythmy/art/massage therapy sessions was 12 (interquartile range
10–20), median therapy duration was 118 days (interquartile range 78–189 days).
From baseline to six-month follow-up, Disease Score improved by average 3.00 points (95% confidence interval
2.76–3.24 points, p < 0.001) and Symptom Score improved by 2.41 points (95% confidence interval 2.16–2.66
points, p < 0.001). These improvements were maintained until the last follow-up. Symptom Score improved
similarly in patients not using adjunctive non-anthroposophic therapies within the first six study months.
Conclusion:  Children under anthroposophic treatment had long-term improvement of chronic disease
symptoms. Although the pre-post design of the present study does not allow for conclusions about comparative
effectiveness, study findings suggest that anthroposophic therapies may play a beneficial role in the long-term care
of children with chronic illness.
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Background
Chronic illness affects 15%–18% of children [1] and can
lead to functional limitation, dependency on therapies
and medication, poor school performance, and impaired
quality of life [1-4]. Strategies to improve the outcome of
chronic paediatric illness include enhanced healthcare
provision [5] and special educational and behavioural
interventions [6-8]. Many children with chronic disease
also receive complementary therapies [9-13], sometimes
provided by their physicians. In Germany, several physi-
cian-provided complementary therapies have been reim-
bursed by health insurance companies as part of special
health benefit programs [14-17]. In most of these comple-
mentary therapies the physician is the active person,
directly treating (e. g. giving acupuncture) or prescribing
therapy (e. g. homoeopathic medications), while the
patient has a predominantly passive role. Anthroposophic
medicine (AM), a complementary system of medicine
founded by Rudolf Steiner and Ita Wegman [18], includes
active (AM art and eurythmy therapy) as well as passive
therapy modalities (massage, medications).
In AM art therapy the patients engage in painting, draw-
ing, clay modelling, music or speech exercises [19]. In
addition to psychological effects (e. g. activation, emotive
expression, dialogical communication with the therapist
and with the artistic medium) [20,21], AM art therapy can
induce physiological effects: e. g. AM speech exercises
have effects on heart rate rhythmicity and cardiorespira-
tory synchronization which are not induced by spontane-
ous or controlled breathing alone [22,23].
Eurythmy therapy (Greek: eurythmy = "harmonious
rhythm") is an active exercise therapy, involving cogni-
tive, emotional, and volitional elements [24]. During
eurythmy therapy sessions the patients are instructed to
perform specific movements with the hands, the feet or
the whole body. Eurythmy movements are related to the
sounds of vowels and consonants, to music intervals or to
soul gestures, e. g. sympathy-antipathy [25]. Eurythmy
exercises have specific effects on heart rate variability [26].
Qualification as an AM art or eurythmy therapist requires
six years' training according to an international, standard-
ised curriculum.
Rhythmical massage therapy was developed from Swedish
massage by Ita Wegman, physician and physiotherapist
[27], and is practiced by physiotherapists with 1 1/2–3
years specialised training. In rhythmical massage therapy,
traditional massage techniques (effleurage, petrissage,
friction, tapotement, vibration) are supplemented by gen-
tle lifting and rhythmically undulating, stroking move-
ments, where the quality of grip and emphasis of
movement are altered to promote specific effects [28].
AM medications are of mineral, botanical or zoological
origin or are chemically defined substances [29].
Prior to prescription of AM medications or referral to AM
therapies, AM physicians have prolonged consultations
with the patients and their caregivers. These consultations
are used to take an extended history, to address constitu-
tional and psychosocial aspect of the patients' illness, to
explore the patients' and caregivers' preparedness to
engage in treatment, and to select optimal therapy for
each patient [19,28].
AM is practiced in 67 countries [30]. Related to the AM
approach is an educational philosophy implemented in
more than 3,000 Waldorf Schools, kindergartens, and cur-
ative education centres worldwide [31,32]. Waldorf
school attendance has been associated with a reduced risk
for atopic disease [33,34], possibly mediated by effects on
the intestinal microflora from restrictive use of antibiotics
and antipyretics in childhood infectious disease [34] or
from a vegetarian diet [35].
Observational studies suggest that AM therapies can have
clinically relevant effects in children with chronic diseases
[24,36-45]. All these studies were monocentric, and all
but four studies [36,37,42,44] had a sample size of 30 or
less AM patients. Here we present a pre-planned subgroup
analysis of 435 children from a multi-centre long-term
study of AM therapy [15].
Methods
Study design and objective
This is a prospective cohort study in a real-world medical
setting. The study was part of a research project on the
effectiveness, costs, and safety of AM therapies in outpa-
tients with chronic disease (Anthroposophic Medicine
Outcomes Study, AMOS) [15,46,47]. The AMOS project
was initiated by a health insurance company in conjunc-
tion with a health benefit program. The present pre-
planned analysis concerned the subgroup of children with
chronic diseases. The primary research question con-
cerned the range of indications for AM therapy as well as
the outcome of disease symptoms. Further research ques-
tions concerned quality of life, use of adjunctive non-AM
therapies, therapy satisfaction, and adverse reactions.
Setting, participants, and therapy
All physicians certified by the Physicians' Association for
Anthroposophical Medicine in Germany and working in
an office-based practice or outpatient clinic were invited
to participate in the AMOS study. Certification as an AM
physician required a completed medical degree and a
three-year structured postgraduate training. The partici-
pating physicians recruited consecutive patients starting
AM therapy under routine clinical conditions. PatientsBMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
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enrolled in the period 1 January 1999 to 31 December
2005 were included in the present analysis if they fulfilled
the eligibility criteria. Inclusion criteria were:
1. Outpatients aged 1–16 years.
2. AM-related consultation of at least 30 minutes fol-
lowed by prescription of AM medication or referral to
AM therapy (art, eurythmy or rhythmical massage) for
any indication (main diagnosis).
3. Duration of main diagnosis of at least 30 days at
study enrolment.
Patients were excluded if they had previously received the
AM therapy in question (see inclusion criteria no. 2) for
their main diagnosis. AM therapy was evaluated as a
whole system [48] with subgroup analysis of evaluable
therapy modality groups.
Primary outcome
Primary outcome was disease severity at six-month fol-
low-up. Disease severity was assessed on numerical rating
scales [49] from 0 („not present“) to 10 („worst possi-
ble“): Disease Score (physicians' global assessment of
severity of main diagnosis); Symptom Score (caregivers'
assessment of severity of one to six most relevant symp-
toms present at baseline). Disease Score was documented
after 0 and 6 months, Symptom Score and quality of life
(see below) after 0, 3, 6, 12, 18, and 24 months.
Secondary outcomes
In patients aged 8–16 years, quality of life was assessed
with self-report, using the KINDL®  Questionnaire for
Measuring Health-Related Quality of Life in Children and
Adolescents, Total Quality of Life Score (0–100). For
patients enrolled up till March 2001 the KINDL 40-item
version [50] was used; for patients enrolled April 2001
and thereafter the KINDL 24-item version [51] (Kid-
KINDL® for age 8–12 years, Kiddo-KINDL® for age 13–16
years) was used. The KINDL questionnaire addresses
physical and emotional well-being, self-esteem, family,
friends, and everyday functioning.
In patients aged < 8 years, quality of life was assessed by
caregivers. For patients enrolled up till March 2001 the
KITA Quality of Life Questionnaire [52] (age 1–7 years)
was used. The KITA questionnaire comprises the subscales
Psychosoma and Daily Life (0–100). For patients enrolled
April 2001 and thereafter Kiddy-KINDL®, Total Quality of
Life Score [51] (age 4–7 years) was used.
Therapy outcome rating (0–10), satisfaction with therapy
(0–10), and therapy effectiveness rating ("very effective,
"effective", "less effective", "ineffective" or "not evalua-
ble") were documented by the caregivers (effectiveness
rating also by the physicians) after 6 and 12 months.
Adverse reactions to medications or therapies were docu-
mented by the caregivers after 6, 12, 18, and 24 months,
and by the physicians after 6 months (for patients
enrolled before 1 April 2001 also after 3, 9, and 12
months). The documentation included suspected cause,
intensity (mild/moderate/severe = no/some/complete
impairment of normal daily activities), and therapy with-
drawal because of adverse reactions. Serious adverse
events (death, life-threatening condition, acute in-patient
hospitalization, new disease or accident causing perma-
nent disability, congenital anomaly, new malignancy)
were documented by the physicians throughout the study.
Data collection
All data were documented with questionnaires returned
in sealed envelopes to the study office. The physicians
documented eligibility criteria; the therapists documented
AM therapy administration; all other items were docu-
mented by the caregivers or patients unless otherwise
stated. The patient responses were not made available to
the physicians. The physicians were compensated 40 Euro
(after March 2001: 60 Euro) per included and fully docu-
mented patient, while the patients and their caregivers
received no compensation.
The data were entered twice by two different persons into
Microsoft® Access 97. The two datasets were compared and
discrepancies resolved by checking with the original data.
Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the
Faculty of Medicine Charité, Humboldt University, Berlin,
Germany, and was conducted according to the Declara-
tion of Helsinki and largely following the ICH Guideline
for Good Clinical Practice E6. Written informed consent
was obtained from all patients before enrolment.
Data analysis
The data analysis was performed on all patients fulfilling
the eligibility criteria, using SPSS® 14.0.1 (SPSS Inc., Chi-
cago, Ill, USA) and StatXact® 5.0.3 (Cytel Software Corpo-
ration, Cambridge, MA, USA). Diagnoses were coded
according to the International Classification of Diseases,
Tenth Revision (ICD-10).
For continuous data the two-tailed t-test was used. For
binominal data the two-tailed McNemar test and Fisher's
exact test were used. Significance criteria were p < 0.05 or
95% confidence interval (95%-CI) not including 0. Since
this was a descriptive study, no adjustment for multiple
comparisons was performed [53].
Pre-post effect sizes were calculated as Standardised
Response Mean (= mean change score divided by the
standard deviation of the change score) and classified asBMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
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minimal (< 0.20), small (0.20–0.49), medium (0.50–
0.79), and large (³ 0.80) [54,55]. In the main analysis,
clinical outcomes were analysed in patients with evalua-
ble data for each follow-up, without replacement of miss-
ing values.
Three pre-planned sensitivity analyses (SA1–SA3) were
performed to assess the influence of patient attrition, nat-
ural recovery, and adjunctive diagnosis-relevant non-AM
therapies on the 0–6-month Symptom Score outcome.
SA1 concerned attrition bias: Missing values after six
months were replaced with the last value carried forward.
SA2 concerned natural recovery, which was assumed to be
unlikely in AMOS patients with disease duration of at
least one year [56]: The sample was therefore restricted to
patients with disease duration of at least 12 months prior
to study enrolment. SA3 concerned the effects of relevant
non-AM therapies, and was performed on diagnosis
groups with at least 15 evaluable patients (mental, respi-
ratory or musculoskeletal diseases, headache syndromes,
urinary incontinence). In SA3 this sample was restricted to
patients not using diagnosis-related non-AM therapies
during the first six study months (listed in Table 1).
Stepwise multiple linear regression analysis was per-
formed to identify predictors of Symptom Score change
from baseline after 6 and 12 months. Criterion for inclu-
sion of variables in the model was p < 0.05 and for exclu-
sion p ³ 0.10. The following independent variables were
analysed:
￿ Socio-demographics: age, gender, household size,
living with father, visiting Waldorf School, health
insurance coverage, year of enrolment.
￿ Disease status at baseline: diagnosis (five categories),
disease duration, disease severity, baseline Symptom
Score, number of comorbid disorders, therapies in the
preceding year (number of AM therapy sessions,
number of patient-months of AM medication and
non-AM medications, respectively, number of sessions
with physiotherapy/occupational therapy/play ther-
apy).
￿ Therapy factors: physician setting (primary care or
other), physician qualification (general practitioner,
paediatrician), number of years since the physician's
medical qualification, previous treatment by the phy-
sician, number of patients enrolled by the physician,
duration of consultation with the physician at study
enrolment, main AM therapy modality (eurythmy, art,
rhythmical massage, medical), number of years since
the AM therapist's qualification, reimbursement of
costs of AM therapies, therapies in months 0–6
Table 1: Diagnosis-related non-anthroposophic therapies in months 0–6
Main diagnosis (International 
Classification of Diseases, 
Tenth Edition)
Non-anthroposophic therapies Patients with therapy
Drugs 
(Anatomical Therapeutic Chemical 
Classification Index)
Non-medication N %
Mental disorders (F00–F99) Antiepileptic, psycholeptic, analeptic, and 
anti-addiction drugs 
(N03A, N05–06, N07B)
Occupational therapy, play 
therapy
31/175 17.7%
Respiratory disorders (J00–J99) Respiratory drugs (H02, J01–02, J04–05, 
J07A, L03, R01, R03, R06–07),
Relevant surgery 18/52 34.6%
Musculoskeletal diseases 
(M00–M99)
Immunosuppressive, musculoskeletal, 
analgesic, and antidepressant drugs 
(L04, M01–05, M09, N02A-B, N06A)
Physiotherapy, relevant 
surgery
3/16 18.8%
Headache disorders 
(G43–G44, R51)
Analgesics, antimigraine drugs, 
antidepressants (C04AX01, C07AA05, 
C07AB02, C08CA06, C08DA01, N02, 
N03AG01, N06A, N07CA03)
0/17 0.0%
Urinary incontinence (R32) Vasopressin and analogues (H01BA) Alarm therapy, occupational 
therapy, play therapy
1/36 2.8%
Total (evaluable patients) 53/296 17.9%BMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
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(number of AM therapy sessions, number of patient-
months of AM medication and non-AM medications,
respectively, number of sessions with physiotherapy/
occupational therapy/play therapy).
Missing values for independent variables were replaced by
the respective mean values. Model assumptions for linear
regression were checked and verified. A few outliers with
studentised residuals ³ 3 standard deviations were identi-
fied and excluded from the analyses (see Results for excep-
tions).
Results
Participating physicians and therapists
The patients were enrolled by 85 physicians with six dif-
ferent qualifications (57 general practitioners, 20 paedia-
tricians, four internists, two otorhinolaryngologists, one
gynaecologist, and one psychiatrist). Comparing these
physicians to AM-certified physicians in Germany with
the same six qualifications but without study patients (n
= 295), no significant differences were found regarding
gender (63.5% vs. 60.3% men), age (mean 46.6 ± 6.5 vs.
48.8 ± 8.3 years), number of years in practice (17.9 ± 7.1
vs. 19.8 ± 9.2 years) or the proportion of physicians work-
ing in primary care (88.2% vs. 83.7%).
The patients were treated by 131 different AM therapists
(art, eurythmy, rhythmical massage). Comparing these
therapists to certified AM therapists in Germany without
study patients (n = 1,046), no significant differences were
found regarding gender (78.6% vs. 81.1% women) or age
(mean 49.4 ± 8.0 vs. 50.4 ± 9.6 years). The number of
years since therapist qualification was 11.1 ± 6.4 and 13.4
± 8.9 years in therapists with and without study patients,
respectively (mean difference 2.3 years, 95%-CI 0.8–3.9
years, p = 0.004).
Patient recruitment and follow-up
From 1 January 1999 to 31 December 2005, a total of 490
patients aged 1–16 years were assessed for eligibility. Of
these patients, 435 fulfilled all eligibility criteria and were
included in the study. 55 patients were not included for
the following reasons: patients' baseline questionnaire
missing (n = 15), physicians' baseline questionnaire miss-
ing (n = 8), patients' and physicians' baseline question-
naire dated > 30 days apart (n = 15), disease duration < 30
days (n = 13), previous or ongoing use of AM therapy in
question (n = 4). Included and not included patients did
not differ significantly regarding age, gender, disease dura-
tion, baseline Disease Score or baseline Symptom Score. A
mental or behavioural disorder (ICD-10: F00–F99) was
more frequent in included than in not included patients
(46.2% vs. 25.5%, p = 0.004).
A total of 54.0% (235 of 435) of patients were enrolled by
general practitioners, 41.4% by paediatricians, and 4.6%
by other specialists. The physicians' settings were primary
care practices (79.0% of evaluable patients, n = 323/409),
referral practices (4.2%), and outpatient clinics (16.9%).
Each physician enrolled 1–4 patients (71%, n = 60/85
physicians), 5–9 patients (20%) or ³ 10 patients (13%),
with a median of 2.0 patients enrolled per physician
(range 1–62 patients, interquartile range [IQR] 1.0–5.5
patients).
The last patient follow-up ensued on 16 February 2008. A
total of 97.5% (n = 424/435) of patients returned at least
one follow-up questionnaire. The patients were adminis-
tered a total of 2,175 follow-up questionnaires, out of
which 1,816 (83.5%) were returned. Follow-up rates were
94.5% (n = 411/435), 88.3%, 83.7%, 77.2%, and 73.8%
after 3, 6, 12, 18, and 24 months, respectively.
Respondents (n = 384) and non-respondents (n = 51) of
the six-month patient-follow-up did not differ signifi-
cantly regarding age, gender, diagnosis, disease duration,
baseline Disease Score or baseline Symptom Score. Corre-
sponding comparisons of respondents (n = 314) and non-
respondents (n = 112) of the 24-month-follow-up also
showed no significant differences, except for baseline Dis-
ease Score which was 6.4 ± 1.8 points in respondents and
6.9 ± 1.7 points in non-respondents (mean difference 0.6
points, 95%-CI 0.2–0.9 points, p = 0.005). The physi-
cians' six-month follow-up documentation was available
for 89.7% (n = 390/435) of patients.
Baseline characteristics
The patients were recruited from 15 of 16 German federal
states. Mean age was 8.2 ± 3.3 years (range 1.0–16.9
years). A total of 58.9% (n = 256/435) of the patients were
boys. Mean household size (including the patient) was
4.2 ± 1.5 persons. A Waldorf school was attended by
50.4% (n = 139/276) of school pupils and by 32.0% of all
patients.
The main diagnosis was a mental disorder (ICD-10: F00–
F99) in 46% of patients (Table 2). Most common diagno-
sis subgroups were F90–F98 Behavioural and emotional
disorders with onset usually occurring in childhood and
adolescence (27.8%, n = 121/435 patients) and F80–F89
Disorders of psychological development (10.1%, n = 44).
Most common three-digit level ICD-10 diagnoses were
F90 Hyperkinetic disorders (16.1%, n = 70/435), R32
Unspecified urinary incontinence (8.7%, n = 38), J45
Asthma (8.0%, n = 35), and F98 Other behavioural and
emotional disorders with onset usually occurring in child-
hood and adolescence (5.1%, n = 22). Median disease
duration was 3.3 years (IQR 1.0–5.0 years, mean 3.4 ± 2.7
years).
A current comorbid disease was present in 63.6% (n =
276/434) of evaluable patients, with a median of 1.0 (IQRBMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
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Table 2: Baseline data of study population
Item N%
Age groups
￿ 1–3 years 32/435 7.4%
￿ 4–7 years 183/435 42.1%
￿ 8–12 years 175/435 40.2%
￿ 13–16 years 45/435 10.3%
Living with
￿ Mother 424/435 97.5%
￿ Father 339/435 77.9%
￿ Siblings 339/435 77.9%
￿ Other persons 50/435 11.5%
￿ More than one person 396/433 91.5%
School pupils
￿ 1st to 3rd form 148/275 53.8%
￿ 4th to 6th form 86/275 31.3%
￿ 7th to 11th form 41/275 4.9%
Health insurance coverage
￿ Statutory 389/434 89.6%
￿ Private 45/434 10.4%
Main diagnosis, International Classification of Diseases, Tenth Edition
￿ F00–F99 Mental and behavioural disorders 201/435 46.2%
￿ R00–R99 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 80/435 18.4%
￿ J00–J99 Diseases of the respiratory system 61/435 14.0%
￿ G00–G99 Diseases of the nervous system 25/435 5.7%
￿ M00–M99 Diseases of the musculoskeletal system and connective tissue 17/435 3.9%
￿ Other 51/435 11.7%
Disease duration
￿ 1–2 months 15/435 3.4%
￿ 3–5 months 15/435 3.4%
￿ 6–11 months 40/435 9.2%
￿ 1–4 years 241/435 55.4%
￿ ³ 5 years 124/435 28.5%BMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
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0.0–2.0) comorbid diseases. The most common comor-
bid diseases were R00–R99 Symptoms, signs and abnor-
mal clinical and laboratory findings, not elsewhere
classified (19.7%, n = 90/458 diagnoses), F00–F99 Men-
tal and behavioural disorders (17.5%), J00–J99 Diseases
of the respiratory system (13.8%), L00–L99 Diseases of
the skin and subcutaneous tissue (9.6%), and D50–D89
Diseases of the blood and blood-forming organs and cer-
tain disorders involving the immune mechanism (6.1%).
Further baseline data are presented in Table 2.
Therapy
At study enrolment, the duration of the consultation with
the AM physician was < 30 min in 53.1% (n = 231/435)
of patients, 30–44 min in 21.1%, 45–59 min in 12.6%,
and ³ 60 min in 13.1% of patients. At enrolment, 16.3%
(n = 71/435) of patients started AM therapy provided by
the physician, while the remaining 83.7% (n = 364) were
referred to AM eurythmy/art/massage therapy. Of these
364 patients, 86.8% (n = 316) had the planned AM ther-
apy, 0.5% (n = 2) did not have AM therapy, and for 12.6%
(n = 46) the AM therapy documentation is incomplete or
inconclusive. AM therapies used were eurythmy therapy
(n = 238 patients), rhythmical massage therapy (n = 29),
and art therapy (n = 49) with the therapy modalities
painting/drawing/clay (n = 17), speech exercises (n = 17),
and music (n = 15). The AM eurythmy/art/massage ther-
apy started median 13 (IQR 3–41) days after enrolment.
Median therapy duration was 118 days (IQR 78–189
days), median number of therapy sessions was 12 (IQR
10–20). AM medications were used by 41.6% (n = 181/
435) of patients in months 0–6 and by 69.2% (n = 301)
in months 0–24.
Use of diagnosis-related non-AM therapies within the first
six study months was analysed in patients with a main
diagnosis of mental, respiratory or musculoskeletal dis-
eases, headache syndromes (ICD-10 G43–G44, R51) or
urinary incontinence, altogether n = 335 patients. Patients
were classified as users if they had used at least one of the
listed therapies (Table 1) for at least one day per month.
Out of 296 evaluable patients, 82.1% (n = 243) had no
diagnosis-related non-AM therapy.
Primary outcome
Disease and Symptom Scores (Figure 1) improved signifi-
cantly and progressively between baseline and all subse-
quent follow-ups. After six months, an improvement of ³
50% of baseline scores was observed in 46.7% (n = 169/
362) and 41.7% (n = 159/381) of evaluable patients for
Disease and Symptom Scores, respectively. Standardised
Response Mean effect sizes for the 0–6 month comparison
were large for both scores (1.30 and 0.97, respectively).
Symptom Score improved significantly in all four therapy
modality groups (medical, eurythmy, art, rhythmical mas-
sage) (Table 3).
We performed three sensitivity analyses of the 0–6 month
outcome of Symptom Score (Table 4: SA1–SA3; see Meth-
ods for further description). SA1+2 had only small effects,
reducing the average improvement by maximum 5%
(2.41® 2.28 points). SA3 increased the improvement by
9% (2.42® 2.63 points). Combining SA1+2+3, Symptom
Score improvement was increased by 5% (2.42® 2.54
points).
Predictors of Symptom Score improvement from baseline
after 6 and 12 months were identified by stepwise multi-
ple linear regression analysis (see Methods for details).
The models for 0–6 month and 0–12 month improve-
ment explained 23% and 26% of the variance, respec-
tively (Table 5). Three variables were significant predictors
in both models:
￿ Symptom Score at baseline: For each 1.00 point
increase in baseline Symptom Score (increase means
worse symptoms), the Symptom Score improvement
will increase by average 0.67 and 0.71 points after 6
and 12 months, respectively. Baseline Symptom Score
was the strongest predictor, explaining 17% and 20%
of the variance after 6 and 12 months, respectively.
￿ Disease Score at baseline: For each 1.00 point
increase in baseline Disease Score (increase means
more severe disease), the Symptom Score improve-
ment will decrease by average 0.18 points and 0.21
points after 6 and 12 months, respectively.
￿ Disease duration: For each year of disease duration
prior to study enrolment, the improvement will
decrease by 0.10 and 0.14 points after 6 and 12
months, respectively.
In addition, the 0–6 month improvement was positively
predicted by the variables 'main AM therapy modality
medical' and 'previous treatment by physician' (these two
predictions disappeared when one identified outlier was
included in the analysis, see Methods for details) and neg-
atively predicted by the number of sessions with physio-
therapy, occupational therapy or play therapy in the
previous year, while the 0–12 month improvement was
positively predicted by enrolment by a general practi-
tioner and negatively predicted by a main diagnosis of
F00–F99 Mental and behavioural disorders.
Secondary outcomes
The quality of life scores in all age groups improved signif-
icantly between baseline and nearly all subsequent fol-
low-ups (23 significant and 2 non-significant
improvements in 25 pre-post comparisons). Effect sizes
for the 0–6 month comparison were medium for KITA
Psychosoma (0.52) and small for the remaining four
scores (range 0.29–0.41, Table 3).BMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
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At six-month follow-up, the caregivers' average therapy
outcome rating (numeric scale from 0 "no help at all" to
10 "helped very well") was 7.12 ± 2.56 and the caregivers'
satisfaction with therapy (from 0 "very dissatisfied" to 10
"very satisfied") was 7.87 ± 2.27.
The caregivers' effectiveness rating of eurythmy, art or
rhythmical massage therapy was positive ("very effective"
or "effective") in 78.8% (n = 242/307) of evaluable
patients who had started therapy, and negative ("less
effective", "ineffective" or "not evaluable") in 21.2%. The
physicians' effectiveness rating was positive in 79.7% (n =
274/344) and negative in 20.3%. From 6- to 12-month
follow-up, caregiver satisfaction with therapy decreased
by average 0.38 points (95%-CI 0.13–0.63, p = 0.003)
whereas caregivers' therapy outcome rating, and caregiv-
ers' as well as physicians' effectiveness rating did not
change significantly.
Adverse reaction to AM therapies were reported in 1.3%
(n = 4/316) of therapy users (eurythmy therapy: n = 2,
rhythmical massage therapy: n = 2). The intensity of these
reactions was moderate (n = 3) or not documented (n =
1); the AM therapy was stopped due to adverse reactions
in two patients (eurythmy therapy: n = 1, rhythmical mas-
sage therapy: n = 1). The frequency of reported adverse
drug reactions was 2.3% (n = 7/301 users) for AM medi-
cations and 8.3% (n = 22/264 users) for non-AM medica-
tions (p = 0.002).
Serious adverse events occurred in five patients. Four
patients were acutely hospitalised and one patient had
permanent disability from a whiplash injury. None of
these events were causally related to any therapy or medi-
cation.
Discussion
This two-year prospective cohort study is the first large
study of AM therapy for children with chronic disease per-
formed in office-based settings. We aimed to obtain infor-
mation on AM therapy under routine conditions in
Germany and studied the disease spectrum and clinical
outcomes in children aged 1–16 years starting AM treat-
ment for chronic diseases. Most frequent indications were
mental/behavioural disorders (primarily hyperkinetic,
emotional, and developmental disorders) and respiratory
diseases. Following AM therapy, statistically significant
improvements of disease symptoms and quality of life
Table 3: Clinical outcomes 0–6 months
Outcome (range) Age years N 0 months 6 months 0–6 month difference* SRM
Mean (SD) Mean (SD) Mean (95%-CI) P-value
Disease Score (0–10) 1–16 362 6.49 (1.75) 3.49 (2.25) 3.00 (2.76–3.24) < 0.001 1.30
Symptom Score (0–10) 1–16
￿ All patients 381 6.21 (1.76) 3.80 (2.34) 2.41 (2.16–2.66) < 0.001 0.97
￿ Medical treatment 60 5.72 (1.56) 2.86 (2.45) 2.86 (2.22–3.50) < 0.001 1.16
￿ Eurythmy therapy 239 6.37 (1.84) 4.04 (2.33) 2.33 (2.02–2.65) < 0.001 0.95
￿ Art therapy 51 6.35 (1.38) 3.86 (2.05) 2.49 (1.90–3.09) < 0.001 1.18
￿ Rhythmical massage therapy 31 5.70 (1.84) 3.73 (2.32) 1.97 (0.82–3.11) 0.001 0.63
KINDL 40-item, Total** (0–100) 8–16 69 67.93 (11.18) 71.83 (11.18) 3.89 (1.43–6.36) 0.002 0.38
KINDL (Kid or Kiddo) Total*** (0–100) 8–16 104 68.48 (13.06) 72.19 (11.35) 3.71 (1.24–6.18) 0.004 0.29
KITA Psychosoma** (0–100) 1–7 80 67.92 (15.21) 75.73 (13.74) 7.81 (4.45–11.18) < 0.001 0.52
KITA Daily Life** (0–100) 1–7 87 59.39 (19.48) 66.14 (19.03) 6.75 (3.00–10.50) 0.001 0.38
KINDL (Kiddy) Total*** (0–100) 4–7 104 67.82 (9.97) 71.78 (9.62) 3.97 (2.07–5.87) < 0.001 0.41
*Positive differences indicate improvement. **Patients enrolled up till 31 March 2001. ***Patients enrolled 1 April 2001 and thereafter. SRM: 
Standardised Response Mean effect size (minimal: < 0.20, small: 0.20–0.49, medium: 0.50–0.79, large: ³ 0.80).BMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
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were observed. The symptom improvement was similar in
patients not using diagnosis-relevant adjunctive non-AM
therapies. A strong positive predictor of improvement
after 6 and 12 months was higher baseline symptom
intensity (caregivers' rating); weaker and negative predic-
tors were higher disease severity (physicians' rating) and
longer disease duration. Adverse reactions to AM thera-
pies and medications were infrequent and not serious.
Strengths of this study include a detailed assessment of the
therapy setting and therapy-related factors, a long follow-
up period, and a high representativeness due to the partic-
ipation of 14% of eligible AM physicians and AM thera-
pists in Germany. The participating physicians and
therapists resembled eligible but not participating AM
physicians and AM therapists with respect to demographic
characteristics, and the included patients resembled not
included patients regarding baseline characteristics
(except for a possible over-representation of mental disor-
ders). These features suggest that the study to a high
degree mirrors contemporary AM use in outpatient set-
tings.
A limitation of the study is the absence of a comparison
group receiving conventional treatment or no therapy.
Accordingly, for the observed improvements one has to
consider several other causes apart from the AM treat-
ment. We therefore conducted a sensitivity analysis of
Symptom Score, estimating the influence of attrition bias,
adjunctive non-AM therapies, and natural recovery. These
three factors together explained only 5% of the improve-
ment. According to a previous analysis from this research
program [56], regression to the mean due to symptom
fluctuation with preferential self-selection to therapy and
study inclusion at symptom peaks explained up till 0.43
points (14%) of the improvement of Disease Score, which
would correspond to approximately 18% of the Symptom
Score improvement in the present analysis. Other possible
confounders are psychological factors and non-specific
effects. However, since AM therapy was evaluated as a
whole system [48], the question of specific therapy effects
vs. non-specific effects (placebo effects, context effects,
Table 4: Symptom Score 0–6 months: sensitivity analyses (SA)
Analysis N 0 months 6 months 0–6 month difference
Mean (SD) Mean (SD) Mean (95%-CI) P-value
Main analysis: Patients with evaluable Symptom Score at 0 and 6 months 381 6.21 (1.76) 3.80 (2.34) 2.41 (2.16–2.66) < 0.001
SA1: Last value carried forward 433 6.15 (1.80) 3.87 (2.35) 2.28 (2.05–2.52) < 0.001
SA2: Patients with disease duration ³ 12 months at study enrolment 320 6.29 (1.76) 3.91 (2.28) 2.39 (2.13–2.65) < 0.001
SA1 + SA2 364 6.24 (1.78) 3.96 (2.30) 2.28 (2.03–2.52) < 0.001
Patients with main diagnosis of mental, musculoskeletal or respiratory 
diseases, headache disorders or urinary incontinence
Main analysis: Patients with evaluable Symptom Score at 0 and 6 months 297 6.26 (1.72) 3.84 (2.35) 2.42 (2.13–2.71) < 0.001
SA3: Patients not using diagnosis-related non-anthroposophic therapies (see 
Table 1) in months 0–6
239 6.32 (1.71) 3.69 (2.29) 2.63 (2.32–2.95) < 0.001
SA1 + SA2 + SA3 204 6.40 (1.71) 3.87 (2.21) 2.54 (2.22–2.86) < 0.001
Disease and Symptom Scores Figure 1
Disease and Symptom Scores. Range: 0 "not present", 
10 "worst possible". Disease Score: physicians' assessment, n 
= 426. Symptom Score: caregivers' assessment, n = 433.
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physician-patient interactions, patient expectations etc.)
was not an issue of the present analysis.
Since patients were treated by AM physicians who could
possibly have an interest in AM therapy having favourable
outcomes, study data were largely collected by the
patients and not the physicians. Any bias affecting the
physicians' documentation would not affect Symptom
Score or quality of life, since these clinical outcomes were
documented by the patients or caregivers.
This analysis assessed AM as a whole system [48], with
subgroup analyses of major therapy modality groups. In
the bivariate analyses, symptom improvement was more
outspoken among patients receiving AM medical therapy
and less outspoken in the rhythmical massage therapy
group (Table 3), but this was not reliably confirmed in the
multivariate predictor analyses. Other measures of varia-
bility of AM treatment, such as the duration of the initial
consultation or the number of AM therapy sessions, did
not predict symptom improvement.
The strongest predictor of symptom improvement was
baseline symptom severity as rated by caregivers. This
finding can have several causes, such as more room for
improvement and more regression to the mean with
higher score values, the hello-goodbye effect, and a higher
patient motivation with therapies working better at higher
symptom levels [55,56]. Baseline disease severity, rated by
the physicians, predicted future improvement in the
opposite direction than baseline symptoms (i. e. lower
disease severity predicted more improvement while lower
Table 5: Predictors of Symptom Score improvement: results of stepwise multiple linear regression analysis
Variable 0–6 months (N = 380) 0–12 months (N = 360)
Adjusted R2 change B 
(95% confidence 
interval)
P-value Adjusted R2 change B 
(95% confidence 
interval)
P-value
Intercept 0.31 (-1.21 to 1.82) 0.690 0.67 (-0.57 to 1.90) 0.290
Symptom Score at 
enrolment (0–10)
0.17 0.67 (0.54 to 0.81) < 0.001 0.20 0.71 (0.58 to 0.84) < 0.001
Disease Score at 
enrolment (0–10)
0.03 -0.18 (-0.32 to -0.05) 0.007 0.02 -0.21 (-0.34 to -0.08) 0.002
Main AM therapy 
modality medical*
0.01 0.81 (0.20 to 1.42) 0.010 --- --- ---
Previous treatment by 
physician*
0.01 0.60 (0.11 to 1.09) 0.016 --- --- ---
Disease duration (years) 0.01 -0.10 (-0.19 to -0.02) 0.018 0.02 -0.14 (-0.23 to -0.05) 0.002
Physiotherapy, 
occupational therapy or 
play therapy in months 
0–6 (sessions)
0.01 -0.03 (-0.05 to -0.003) 0.029 --- --- ---
Main diagnosis F00–F99 
Mental and behavioural 
disorder*
--- --- --- 0.02 -0.65 (-1.08 to -0.22) 0.003
Enrolment by general 
practitioner*
--- --- --- 0.01 0.58 (0.14 to 1.02) 0.010
Total R2 0.23 Total R2 0.26
Analysis of variance 
for model
F-value P-value F-value P-value
19,727 < 0.001 26,641 < 0.001
Adjusted R2: Adjusted coefficient of multiple determination. B: regression coefficient. *: 0 = no, 1 = yes. ---: Variable not included in the model.BMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
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symptom intensity predicted less improvement). A possi-
ble explanation for this seeming paradox is that physi-
cians incorporate medical knowledge about the patients'
prognosis into their severity rating, while caregivers focus
more strongly on the symptoms. – A limitation of the pre-
dictor analysis is that parental education and occupa-
tional levels as well as household income could not be
assessed, since these items were not documented for chil-
dren. In a corresponding predictor analysis in adult
patients from the AMOS project, these factors were not
associated with symptom improvement (Hamre et al, sub-
mitted for publication).
Previous studies have evaluated AM therapy for children
with chronic disorders including anorexia nervosa
[36,38], atopic diseases [37,43], hyperkinetic disorders
[24,45], epilepsy [44], hepatitis B [39], and immune sup-
pression with recurrent respiratory infections following
radioactive exposure after the Chernobyl nuclear accident
[40-42]. All these studies had some favourable outcomes;
the three largest studies (range 79–125 AM patients)
found high anorexia cure rates [36], reduced infection
rates and normalisation of immune parameters in Cher-
nobyl children [42], and successful epilepsy therapy with-
out conventional anticonvulsive drugs [44]. Except for a
pilot study with five patients [24], these studies were per-
formed in inpatient hospitals [36-39] or outpatient clinics
[40-45]. In accordance with these studies from secondary
care, our study from a predominantly primary care setting
showed significant improvements of mental/behavioural,
respiratory, and other chronic diseases in children follow-
ing AM treatment. The largest improvements (large effect
sizes, half of patients improved by at least 50% of their
baseline scores) were observed for the items which
directly measure the conditions treated with AM, i. e. Dis-
ease and Symptom Scores.
This study also underlines the role of naturalistic outcome
studies in the evaluation of complementary therapies and
other complex therapy systems [57,58]. For such outcome
studies, several features are called for [48,57-60], which
are found in the present study: primary assessment of the
whole therapy complex and secondary assessment of ther-
apy components; recruitment of patients in the setting
where they are usually treated (here: predominantly pri-
mary care); documentation of routine therapy practice
while minimising distortion from experimental study
conditions; widely used outcomes (here: numerical rating
scales); long-term follow-up; and, especially in the case of
single-arm studies, a systematic approach to assess and
minimise bias.
Conclusion
In this study, children under AM treatment for mental/
behavioural, respiratory, and other chronic diseases had
long-term reduction of disease severity and improvement
of quality of life. Improvements were similar in patients
not using adjunctive non-AM therapies. Although the pre-
post design of the present study does not allow for conclu-
sions about comparative effectiveness, study findings sug-
gest that AM therapies may play a beneficial role in the
long-term care of children with chronic illness.
List of abbreviations
±: standard deviation; 95%-CI: 95% confidence interval;
AM: Anthroposophic Medicine; AMOS: Anthroposophic
Medicine Outcomes Study; ICD-10: International Classi-
fication of Diseases, Tenth Edition; IQR: interquartile
range; KINDL: KINDL®  Questionnaire for Measuring
Health-Related Quality of Life in Children and Adoles-
cents; SA: Sensitivity analysis.
Competing interests
Within the last five years HJH and GSK have received
restricted research grants and CM has received lecture fees
from the pharmaceutical companies Weleda and Wala,
who produce AM medications. Otherwise all authors
declare that they have no competing interests.
Authors' contributions
HJH, CMW, GSK, SNW, and HK contributed to study
design. HJH, AG, CM, and HK contributed to data collec-
tion. HJH and HK wrote the analysis plan, HJH and AG
analysed data. HJH was principal author of the paper, had
full access to all data, and is guarantor. All authors con-
tributed to manuscript drafting and revision and
approved the final manuscript.
Acknowledgements
This study was funded by the Software-AG Stiftung and the Innungskrank-
enkasse Hamburg, with supplementary grants from the Helixor Stiftung, the 
Mahle Stiftung, and the Zukunftsstiftung Gesundheit. The sponsors had no 
influence on design and conduct of the study; collection, management, anal-
ysis or interpretation of the data; or preparation, review or approval of the 
manuscript. Our special thanks go to the study physicians, therapists, and 
patients for participating.
References
1. Judson L: Global childhood chronic illness.  Nurs Adm Q 2004,
28:60-66.
2. Yeo M, Sawyer S: Chronic illness and disability.  BMJ 2005,
330:721-723.
3. Janse AJ, Sinnema G, Uiterwaal CS, Kimpen JL, Gemke RJ: Quality of
life in chronic illness: perceptions of parents and paediatri-
cians.  Arch Dis Child 2005, 90:486-491.
4. Ravens-Sieberer U, Ellert U, Erhart M: Gesundheitsbezogene
Lebensqualität von Kindern und Jugendlichen in Deutsch-
land. Eine Normstichprobe für Deutschland aus dem Kinder-
und Jugendgesundheitssurvey (KIGGS).  Bundesgesundheitsblatt
Gesundheitsforschung Gesundheitsschutz 2007, 50(5-6):810-818.
5. Stein RE: Challenges in long-term health care for children.
Ambul Pediatr 2001, 1:280-288.
6. Fielding D, Duff A: Compliance with treatment protocols:
interventions for children with chronic illness.  Arch Dis Child
1999, 80:196-200.BMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
Page 12 of 13
(page number not for citation purposes)
7. Barlow JH, Ellard DR: Psycho-educational interventions for chil-
dren with chronic disease, parents and siblings: an overview
of the research evidence base.  Child Care Health Dev 2004,
30:637-645.
8. Costello I, Wong IC, Nunn AJ: A literature review to identify
interventions to improve the use of medicines in children.
Child Care Health Dev 2004, 30:647-665.
9. Ernst E: Prevalence of complementary/alternative medicine
for children: a systematic review.  Eur J Pediatr 1999, 158:7-11.
10. Simpson N, Roman K: Complementary medicine use in chil-
dren: extent and reasons. A population-based study.  Br J Gen
Pract 2001, 51:914-916.
11. Bode H, Muller O, Storck M: Complementary/alternative med-
icine in chronic paediatric diseases – prevalence and parental
psychological factors.  Pediatr Rehabil 2001, 4:37-38.
12. McCann LJ, Newell SJ: Survey of paediatric complementary and
alternative medicine use in health and chronic illness.  Arch
Dis Child 2006, 91:173-174.
13. Madsen H, Andersen S, Nielsen RG, Dolmer BS, Host A, Damkier A:
Use of complementary/alternative medicine among paediat-
ric patients.  Eur J Pediatr 2003, 162:334-341.
14. Guthlin C, Lange O, Walach H: Measuring the effects of acu-
puncture and homoeopathy in general practice: an uncon-
trolled prospective documentation approach.  BMC Public
Health 2004, 4:6.
15. Hamre HJ, Becker-Witt C, Glockmann A, Ziegler R, Willich SN,
Kiene H: Anthroposophic therapies in chronic disease: The
Anthroposophic Medicine Outcomes Study (AMOS).  Eur J
Med Res 2004, 9:351-360 [http://ifaemm.de/Abstract/PDFs/
HH04_2.pdf].
16. Witt C, Keil T, Selim D, Roll S, Vance W, Wegscheider K, Willich SN:
Outcome and costs of homoeopathic and conventional
treatment strategies: a comparative cohort study in patients
with chronic disorders.  Complement Ther Med 2005, 13:79-86.
17. Moebus S, Lehmann N, Bodeker W, Jöckel KH: An analysis of sick-
ness absence in chronically ill patients receiving complemen-
tary and alternative medicine: a longterm prospective
intermittent study.  BMC Public Health 2006, 6:28.
18. Steiner R, Wegman I: Extending practical medicine. Fundamental princi-
ples based on the science of the spirit. GA 27. [First published 1925] Bris-
tol: Rudolf Steiner Press; 2000. 
19. Evans M, Rodger I: Anthroposophical medicine: Healing for body, soul and
spirit London: Thorsons; 1992. 
20. Petersen P: Der Therapeut als Künstler. Ein integrales Konzept von Psy-
chotherapie und Kunsttherapie Paderborn: Junfermann-Verlag; 1994. 
21. Treichler M: Mensch – Kunst – Therapie. Anthropologische, medizinische
und therapeutische Grundlagen der Kunsttherapien Stuttgart: Verlag
Urachhaus; 1996. 
22. Bettermann H, von Bonin D, Frühwirth M, Cysarz D, Moser M:
Effects of speech therapy with poetry on heart rate rhyth-
micity and cardiorespiratory coordination.  Int J Cardiol 2002,
84:77-88.
23. Cysarz D, von Bonin D, Lackner H, Heusser P, Moser M, Bettermann
H: Oscillations of heart rate and respiration synchronize dur-
ing poetry recitation.  Am J Physiol Heart Circ Physiol 2004,
287:H579-H587.
24. Majorek M, Tüchelmann T, Heusser P: Therapeutic Eurythmy-
movement therapy for children with attention deficit hyper-
activity disorder (ADHD): a pilot study.  Complement Ther Nurs
Midwifery 2004, 10:46-53.
25. Kirchner-Bockholt M: Fundamental principles of curative eurythmy Lon-
don: Temple Lodge Press; 1977. 
26. Seifert G, Driever PH, Pretzer K, Edelhauser F, Bach S, Laue HB, Lan-
gler A, Musial-Bright L, Henze G, Cysarz D: Effects of complemen-
tary eurythmy therapy on heart rate variability.  Complement
Ther Med 2009, 17:161-167.
27. Hauschka-Stavenhagen M: Rhythmical massage as indicated by Dr. Ita
Wegman Spring Valley, NY: Mercury Press; 1990. 
28. Ritchie J, Wilkinson J, Gantley M, Feder G, Carter Y, Formby J: A
model of integrated primary care: anthroposophic medicine London:
Department of General Practice and Primary Care, St Bartholomew's
and the Royal London School of Medicine, Queen Mary, University of
London; 2001. 
29. Anthroposophic Pharmaceutical Codex APC Second edition. Dornach:
The International Association of Anthroposophic Pharmacists IAAP;
2007. 
30. Derzeitige Ausbreitung der Anthroposophisch-
Medizinischen Bewegung.  In 1924–2004 Sektion für Anthroposo-
phische Medizin. Standortbestimmung/Arbeitsperspektiven Edited by:
Glöckler M. Dornach, Freie Hochschule für Geisteswissenschaft;
2004:7-9. 
31. Waldorfschulen weltweit 2009 [http://www.waldorfschule.info/de/schu
len/index.html]. Stuttgart: Bund der Freien Waldorfschulen
32. List of centers 2009 [http://www.khsdornach.org/en/evz/]. Dornach:
Council for Curative Education and Social Therapy
33. Alm JS, Swartz J, Lilja G, Scheynius A, Pershagen G: Atopy in chil-
dren of families with an anthroposophic lifestyle.  Lancet 1999,
353:1485-1488.
34. Flöistrup H, Swartz J, Bergstrom A, Alm JS, Scheynius A, van Hage M,
Waser M, Braun-Fahrlander C, Schram-Bijkerk D, Huber M, et al.:
Allergic disease and sensitization in Steiner school children.
J Allergy Clin Immunol 2006, 117:59-66.
35. Alm JS, Swartz J, Björksten B, Engstrand L, Engstrom J, Kühn I, Lilja G,
Mollby R, Norin E, Pershagen G, et al.: An anthroposophic lifestyle
and intestinal microflora in infancy.  Pediatr Allergy Immunol 2002,
13:402-411.
36. Kienle GS, Kiene H, Albonico HU: Schäfer 1997 [Catamnestic
survey of patients with anorexia nervosa: Treatment out-
come and social rehabilitation. Dissertation].  In Anthroposophic
medicine: effectiveness, utility, costs, safety Stuttgart, New York, Schat-
tauer Verlag; 2006:96-100. 
37. Knol MGP: Die Behandlung von Kindern mit Asthma und/oder Ekzem. For-
schungsjahr "Anthroposophische Kinderheilkunde" am Gemeinschaftsk-
rankenhaus Herdecke 1. August 1988 bis 01. August 1989 Herdecke:
Gemeinschaftskrankenhaus Herdecke; 1989. 
38. Schmitz S: Der anthroposophische Ansatz zur Therapie von Magersucht –
Eine alternative Behandlungsmethode und ihre Erfolge. Dissertation Ham-
burg: Universität Hamburg; 1989. 
39. Sienkiewicz D, Kacmarski M, Lebenszteijn DM: Natural therapy of
children with chronic persistent hepatitis B. Preliminary
report.  Med Sci Monit 1997, 3:446-450.
40. Lukyanova EM, Chernyshov VP, Omelchenko LI, Slukvin II, Pochinok
TV, Antipkin JG, Voichenko IV, Heusser P, Schniedermann G: Die
Behandlung immunsupprimierter Kinder nach dem Tsche-
mobyl-Unfall mit Viscum album (Iscador): klinische und
immunologische Untersuchungen.  Forsch Komplementärmed
1994:58-70.
41. Chernyshov VP, Omelchenko LI, Heusser P, Slukvin II, Vodyanik MA,
Galazyuk LV, Vykhovanets EV, Pochinok TV, Chernychov AV, Gur-
menyuk ME, et al.:  Immunomodulatory  actions of Viscum
album (Iscador) in children with recurrent respiratory dis-
ease as a result of the Chernobyl nuclear accident.  Comple-
ment Ther Med 1997, 5:141-146.
42. Chernyshov VP, Heusser P, Omelchenko LI, Chernyshova LI, Vody-
anik MA, Vykhovanets EV, Galazyuk LV, Pochinok TV, Gaiday NV,
Gumenyuk ME, et al.: Immunomodulatory and clinical effects of
Viscum album (Iscador M and Iscador P) in children with
recurrent respiratory infections as a result of the Chernobyl
nuclear accident.  Am J Ther 2000, 7:195-203.
43. Kienle GS, Kiene H, Albonico HU: Ecker 2001 [Anthroposophi-
cal asthma therapy: A comparison. Is it as good as inhalative
corticosteroids?].  In Anthroposophic medicine: effectiveness, utility,
costs, safety Stuttgart, New York, Schattauer Verlag; 2006:101-104. 
44. Madeleyn R: Gesichtspunkte zur Epilepsie und deren Behand-
lungsmöglichkeit bei Kindern.  Der Merkurstab 1990, 43:369-384.
45. Seeskari D, Michelsson K: Art therapy for children with ADHD and asso-
ciated symptoms Helsinki: MBD-infocenter; 1998. 
46. Hamre HJ, Witt CM, Glockmann A, Ziegler R, Willich SN, Kiene H:
Health costs in anthroposophic therapy users: a two-year
prospective cohort study.  BMC Health Serv Res 2006, 6:65.
47. Hamre HJ, Witt CM, Glockmann A, Tröger W, Willich SN, Kiene H:
Use and safety of anthroposophic medications in chronic dis-
ease: a 2-year prospective analysis.  Drug Saf 2006,
29:1173-1189.
48. Boon H, MacPherson H, Fleishman S, Grimsgaard S, Koithan M, Nor-
heim AJ, Walach H: Evaluating complex healthcare systems: a
critique of four approaches.  eCAM 2007, 4:279-285.
49. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Ander-
son JA: Studies with pain rating scales.  Ann Rheum Dis 1978,
37:378-381.
50. Ravens-Sieberer U, Bullinger M: Assessing health-related quality
of life in chronically ill children with the German KINDL: firstPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pediatrics 2009, 9:39 http://www.biomedcentral.com/1471-2431/9/39
Page 13 of 13
(page number not for citation purposes)
psychometric and content analytical results.  Qual Life Res
1998, 7:399-407.
51. Ravens-Sieberer U, Bullinger M: KINDL® English. Questionnaire for
Measuring Health-Related Quality of Life in Children and Adolescents.
Revised Version. Manual Berlin: Robert Koch Institute; 2000. 
52. Wittorf M: KITA – Fragebogen zur Erfassung der gesundheitsbezogenen
Lebensqualität von Kleinkindern zwischen 1 und 6 Jahren. Dissertation Ber-
lin: Institut für Arbeits-, Sozialmedizin und Epidemiologie der
Medizinischen Fakultät Charité der Humboldt-Universität zu Berlin;
2001. 
53. Feise RJ: Do multiple outcome measures require p-value
adjustment?  BMC Med Res Methodol 2002, 2:8.
54. Cohen J: Statistical power analysis for the behavioral sciences Hillsdale,
NJ: Lawrence Erlbaum; 1988. 
55. McDowell I, Newell C: Measuring health. A guide to rating scales and
questionnaires New York – Oxford: Oxford University Press; 1996. 
56. Hamre HJ, Glockmann A, Kienle GS, Kiene H: Combined bias sup-
pression in single-arm therapy studies.  J Eval Clin Pract 2008,
14:923-929.
57. Heusser P: Kriterien zur Beurteilung des Nutzens von kom-
plementärmedizinischen Methoden.  Forsch Komplementarmed
Klass Naturheilkd 2001, 8:14-23.
58. Walach H, Jonas WB, Lewith GT: The role of outcomes research
in evaluating complementary and alternative medicine.
Altern Ther Health Med 2002, 8:88-95.
59. Shadish WR, Cook TD, Campbell DT: Experimental and quasi-experi-
mental designs for generalized causal inference Boston, MA: Houghton
Mifflin Company; 2002. 
60. Fønnebø V, Grimsgaard S, Walach H, Ritenbaugh C, Norheim AJ,
MacPherson H, Lewith G, Launsø L, Koithan M, Falkenberg T, et al.:
Researching complementary and alternative treatments –
the gatekeepers are not at home.  BMC Med Res Methodol 2007,
7:7.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2431/9/39/prepub